Vaqta


Also found in: Acronyms.

Vaqta

A vaccine against HAV made of killed hepatitis A virus to stimulate the body's immune system to produce antibodies against HAV. See Hepatitis A.

VAQTA

(văk′tă)
Hepatitis A vaccine, inactivated.
References in periodicals archive ?
The younger age indication for VAQTA is supported by the results of an open-label study of children with no evidence of hepatitis A infection.
In this study of 617 children 12-23 months of age, 343 children were evaluated for indicators of an immune response to VAQTA after the second dose of a two dose series.
25U) of VAQTA alone or in combination with other routinely recommended pediatric vaccines, the most commonly reported complaints (>2 percent of injections) after one or both of the doses of VAQTA were localized injection-site reactions (pain/tenderness/soreness), fever, diarrhea, vomiting, irritability, upper respiratory infection, rhinorrhea, cough, rash and otitis media.
As with any vaccine, vaccination with VAQTA may not result in a protective response in all people.
As with any vaccine, there is the possibility that use of VAQTA in very large populations might reveal adverse experiences not observed in clinical trials.
For details about the indications, contraindications, warnings, precautions, adverse reactions and dosage and administration for VAQTA, please read the attached prescribing information.
Within the limits of current assay variability, the 50U dose of VAQTA contains less than 0.
Protection after vaccination with VAQTA has been associated with the onset of seroconversion ((>=)10 mIU/mL of hepatitis A antibody, measured by a modification of the HAVAB** radioimmunoassay (RIA)(2)) and with an anamnestic antibody response following booster vaccination with VAQTA.
A very high degree of protection has been demonstrated after a single dose of VAQTA in children and adolescents.
In subjects who were initially seronegative, the protective efficacy of a single dose of VAQTA was observed to be 100% with 21 cases of clinically confirmed hepatitis A occurring in the placebo group and none in the vaccine group (p<0.
Results from the study to lower the age indication for VAQTA indicated that 100% of 343 initially seronegative children aged 12-23 months who received 2 doses of VAQTA had seroconverted to antibody levels previously indicated to be protective.
In combined clinical trials reported as part of the labeling change application, 706 healthy children aged 12-23 months received [greater than or equal to] doses of VAQTA alone or in combination with other routinely recommended pediatric vaccines.